ClinicalTrials.gg
Active, not recruitingNCT05928390PASIPHYUpdated Sep 17, 2026

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

A Phase 2 interventional study of Pasireotide Diaspartate in Post-Bariatric Hypoglycemia, sponsored by RECORDATI GROUP. Active, not recruiting at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by RECORDATI GROUP · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 294 studies in Hypoglycemia with a site in United States — 36 open to participants now, 49 under way, 5 of them phase 3. Hypoglycemia · United States.

Enrollment
51st of 239
93 · median 24
Started
2024
with 14 others
Phase 2
38 of 294
3 open now
Primary completion
2026-10
later than 16 of 47 live
Registered
258th of 294
by date

Among the 294 studies in Hypoglycemia with a site in United States, this one is the 51st largest by enrollment of the 239 interventional ones that give a count, is one of 15 that started in 2024, is one of 38 in phase 2, reaches primary completion later than 16 of the 47 other live ones, and was the 258th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

36 of the 294 studies in Hypoglycemia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Hypoglycemia with a site in United States, or all of them as a file.
02

Study summary

The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods

  • 19 weeks for the Core Phase. It is composed of:

    • a Screening period: a maximum of 3 weeks
    • a Run-in period (no treatment): 4 weeks
    • a Blinded Treatment Phase: 12 weeks
  • 36 weeks Extension Phase = an open-label Treatment period
  • 4 weeks for the safety follow-up period (without any treatment).
Read the detailed description

Subjects with post-bariatric hypoglycemia will be screened for participation in this trial. Eligible patients will complete the rest of the Core phase by entering a run-in period of 4 weeks without any treatment.

At the end of the run-in period, participants will be randomized to receive in a blinded manner either pasireotide 50 µg or pasireotide 100 µg or pasireotide 200 µg or Placebo subcutaneously three times a day (prior to each meal).

Participants will blindly self-administer their treatment for a total of 12 weeks when the primary endpoint will be assessed.

All participants completing the core phase will be offered to enter the extension phase. Participants will openly self-administer pasireotide 50 µg or pasireotide 100 µg or pasireotide 200 µg subcutaneously three times a day for a total of 36 weeks of treatment. There will be no more placebo during this extension phase of treatment.

Dose changes/adjustments will be possible only during the extension phase and the decision to change the dose of pasireotide will be left to the investigator's judgment.

All participants will come for a safety visit after discontinuation or completion of treatment.

03

Conditions studied

  • Post-Bariatric Hypoglycemia

Browse trials for

Keywords

  • PBH
  • Post Bariatric
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or- non-pregnant female patients ≥ 18 years of age
  2. Patients able to provide and have provided signed written prior to study participation.
  3. Patients capable of self-injecting subcutaneously. Specific training to self-inject the study drug will be provided.
  4. Post-bariatric surgery more than 6 months prior to screening
  5. Patients with a medically documented diagnosis of PBH and documented glucose measurement (less than 70 mg/dl or 3.9 mmol/L) with symptoms of hypoglycaemia, and resolution following administration of rescue carbohydrates
  6. Patients must have ≥ 4 post-prandial hypoglycaemia during the 28-day run-in period (in average ≥1 event over a 7-day week) defined as:

    • Blood glucose less than 54 mg/dL (3.0 mmol/L) as measured by SMBG (level 2) or
    • Level 3 hypoglycaemic event
  7. (The previous inclusion criterion number 7 has been deleted).
  8. Patients in whom dietary control has not sufficiently controlled symptoms of PBH.
  9. Performance Status ≥ 60 (i.e., requires occasional assistance, but is able to care for most of their personal needs)
  10. Patients who received other therapies for PBH (such as acarbose, gama guar, pectin, diazoxide) must have stopped all treatments and such treatments are prohibited for a period of at least 2 weeks or 5 half-life times prior to entering the screening period.
  11. GLP-1 antagonists and GLP-1 agonists for patients who have been treated with in the past for the indication of PBH, are prohibited for a period of at least 4 weeks before the start of the screening period.
  12. SGLT2 inhibitors (glifozins) for patients who have been treated with in the past for the indication of PBH, are prohibited for a period of at least 4 weeks before the start of the screening period.
  13. Patients who have been treated with somatostatin receptor analogues in the past, must have an appropriate interval between the last administration of somatostatin receptor analogues treatment and the start of the run-in period as follows:

    • Octreotide s.c. for ≥ 72 hours
    • Octreotide LAR for ≥ 56 days (8 weeks)
    • Lanreotide Autogel for ≥ 98 days (14 weeks)
    • Lanreotide SR ≥ 28 days (4 weeks)
    • Pasireotide s.c. for ≥ 72 hours (3 days)
    • Pasireotide LAR for ≥ 84 days (12 weeks)

Exclusion criteria

Exclusion Criteria :

  1. Bariatric patients who have lap band.
  2. Patients with a current diagnosis of uncontrolled Diabetes Mellitus. However, diabetic patients in remission, as defined below, are eligible:

    • With an at screening less than 6.5%
    • Not taking any medications for hyperglycaemia for at least 3 months prior to screening.
    • Their qualifying Level 3 hypoglycaemia events (see above) must have occurred at least 1 month after the discontinuation of the glucose lowering agent(s).
  3. Patients with hypocortisolism, as defined by serum cortisol levels minor of LLN with presence of clinical signs and symptoms of adrenal insufficiency (e.g., weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatremia, or hypoglycaemia) as judged by the Investigators
  4. (The previous exclusion criterion number 4 has been deleted).
  5. (The previous exclusion criterion number 5 has been deleted).
  6. Patients who have a known to somatostatin receptor analogues.
  7. Patients currently using medications that may interfere with glucose metabolism within 5 half-lives of drug.
  8. Patients with history of or current insulinoma.
  9. Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study such as:

    • Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive test result (ELISA and Western blot). An HIV test will not be required; however, previous medical history will be reviewed.
    • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment.
    • Life-threatening and ischemic disorders.
    • Inadequate end organ function as defined by:
    • Inadequate bone marrow function:
    • WBC less than 3.0 x 109/L
    • (ANC) less than 1.5 x 109/L
    • less than100 x 109/L
    • less than 11 g/dL
    • ≥ 1.5
    • less than 30 mL/min/1.73m2
    • Alkaline phosphatase more than 2.5 x
    • Serum total more than1.5 x ULN
    • and AST more than 1.5 x ULN
  10. History of liver disease, such as cirrhosis or chronic active andC
  11. Presence of Hepatitis B surface antigen (HbsAg) and/ or Presence of antibody test (anti-HCV). Patients with positive HCV Ab must undergo reflex HCV RNA testing, and patients with HCV RNA positivity will be excluded. Patients with positive HCV Ab and negative HCV RNA are eligible.
  12. History of, or current alcohol and/or drug misuse/abuse within the past 12 months. A drug/alcohol test will not be required; however, previous medical history will be reviewed.
  13. Patients with symptomatic cholelithiasis and/ or acute or chronic pancreatitis.
  14. Patients with abnormal coagulation (PT and PTT elevated by 30% above normal limits).
  15. Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a of at least 10 days and have confirmed normal coagulation parameters before study inclusion (patients receiving aspirin once a day are allowed to be enrolled).
  16. Patients who are hypothyroid and not on adequate replacement therapy.
  17. Patients who have undergone major surgery/surgical therapy for any cause within 1 month before screening. Patients should have recovered from the surgery and be in good clinical condition before entering the study.
  18. Patients requiring gastrostomy tube feedings.
  19. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study.
  20. abnormal laboratory values considered by the Investigator or the medical monitor of the sponsor to be clinically significant or which could have affected the interpretation of the study results.
  21. Bradycardia and -related exclusion criteria:

    • Patients with long QT syndrome or QTcF more than 450 ms for male and QTcF more than 460 ms for female detected at screening.
    • Patients with uncontrolled or significant cardiac disease, including recent myocardial infarction, unstable angina, congestive heart failure, clinically significant/symptomatic heart rate less than50 bpm, or high-grade AV block, sustained ventricular tachycardia, ventricular fibrillation.
    • History of syncope or family history of idiopathic sudden death.
    • Sustained or clinically significant cardiac arrhythmias.
    • Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson\'s disease), HIV, cirrhosis, uncontrolled hypothyroidism, or cardiac failure.
    • Family history of long QT syndrome.
    • Concomitant medications known to prolong the QT interval.
    • Hypokalaemia (Potassium less than or = 3.5 mEq/L).
    • Hypomagnesemia (Magnesium less than 0.7 mmol/L).
  22. Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation. (Use of an drug within 1 month prior to screening).
  23. Significant acute illness within the two weeks prior to dosing.
  24. Female patients who are pregnant, intending to become pregnant or breastfeed during the study. or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  25. Women of (WOCBP) who are unwilling of using highly effective methods.

    Highly effective contraception methods include:

    • Combined (estrogen and progesterone containing) (oral, intravaginal, transdermal) hormonal contraception associated with inhibition of ovulation.
    • Progesterone-only hormonal (oral, injectable, implantable) contraception associated with inhibition of ovulation.
    • Intrauterine device.
    • Intrauterine hormone-releasing system.
    • Bilateral tubal occlusion.
    • Sexual abstinence defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient.
  26. Sexually active males unwilling to use a condom during intercourse while taking the drug and for 4 weeks after pasireotide s.c. last dose. A condom is required to be used also by vasectomized men to prevent delivery of the drug via seminal fluid.
  27. Potentially unreliable or vulnerable patients (e.g., person kept in detention) and those judged by the Investigator to be unsuitable for the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Pasireotide s.c. 50 mcg

    Pasireotide 50 mcg s.c. tid

    Drug: Pasireotide Diaspartate

  • Experimental
    Pasireotide 100 mcg

    Pasireotide 100 mcg s.c. tid

    Drug: Pasireotide Diaspartate

  • Experimental
    Pasireotide 200 mcg

    Pasireotide 200 mcg s.c. tid

    Drug: Pasireotide Diaspartate

  • Placebo comparator
    Placebo

    Placebo s.c. tid

    Drug: Pasireotide Diaspartate

Interventions

  • DrugPasireotide Diaspartate

    Injectable ampoules

    Also known as: Pasireotide

06

What researchers measure

Primary outcomes

  1. Evaluation of the efficacy of pasireotide s.c. on blood glucose concentration during an MMTT in patients with PBH after 12 weeks of treatment.

    Change in the blood glucose levels, as measured by the peak to nadir glucose AUC during MMTT

    Time frame: at baseline and at 12 weeks

Secondary outcomes

  1. KEY SECONDARY_CORE PHASE: Evaluation the change of blood glucose nadir and peak during a mixed meal tolerance test (MMTT) at baseline

    Change from baseline in the rate of the composite (and individual components) of clinically significant hypoglycaemic events as measured as the frequency of level 2 hypoglycaemic events (glucose level \<54 mg/dL or 3.0 mmol/L) measured by SMBG OR the frequency of level 3 hypoglycaemic (requiring external assistance) events/4-weeks at 12 weeks of treatment with pasireotide vs placebo

    Time frame: at baseline and at 12 weeks

  2. CORE PHASE: Evaluation of the change of blood glucose nadir and peak during a mixed meal tolerance test (MMTT) at baseline and the MMTT

    Change in the nadir and peak of blood glucose levels,

    Time frame: baseline and 12 weeks

  3. CORE PHASE: Evaluation of the efficacy of pasireotide s.c. on the change from baseline of level 2 hypoglycaemic events during a MMTT in patients with PBH

    Change from baseline in the proportion of patients with no level 2 hypoglycaemic events (plasma glucose \<54 mg/dL or 3.0 mmol/L) at 60, 90, 105, 120, 135, 150, 165 and 180 min during a 3-hour MMTT

    Time frame: at 12 weeks

  4. CORE PHASE: Assessessment of the effect of pasireotide s.c. on HRQoL (SF-36 score)

    The 36-item Short Form Health Survey (SF-36) is a patient reported outcomes measure that consists of a 36-item self-report inventory. The SF-36 is an accepted metric for benchmarking indications against normative population-based statistics. It assesses health-related limitations in eight dimensions: physical functioning (PF), role limitations due to physical functioning (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Two summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS), can be calculated from the eight-dimension scores (scale scores).

    Time frame: at 12 weeks

  5. CORE PHASE: Assessessment of the effect of pasireotide s.c. on HRQoL (Dumping Score Questionnaire)

    DSQ is a disease specific patient reported outcome (PRO) scale that was developed according to the FDA and EMEA guidelines. The questionnaire utilizes a 5-point Likert scale (0, none; 1, mild; 2, moderate; 3, severe; and 4, very severe) to ask a patient to evaluate the intensity of 10 early dumping symptoms (within 30 minutes (\<30 minutes) after food ingestion). In addition, the questionnaire also evaluates 5 late dumping symptoms (more than 1.5 hours (\>90 minutes) after food ingestion

    Time frame: at 12 weeks

  6. CORE PHASE: Assessessment of the effect of pasireotide s.c. on HRQoL (Patient Global Assessment)

    It will incorporate a patient global assessment question: "Considering all the way that your disease affects you, rate how you are feeling during the last 7 days compared with your situation before starting the study?" Patients Global Assessment will be measured utilizing a 7-point scale (from 1= a lot worse to 7= a lot better).

    Time frame: at 12 weeks

  7. CORE PHASE: Assessessment of the effect of pasireotide s.c. on HRQoL (Hypoglycaemia Fear Survey-II) from baseline

    The Hypoglycaemia Fear Survey (HFS) originally was developed to measure behaviours and worries related to fear of hypoglycaemia (FOH) in adults with type 1 diabetes. Both the original HFS (HFS-I) and the revised version (HFS-II) are composed of two subscales, the Behaviour (HFS-B) and Worry (HFS-W).

    Time frame: at 12 weeks

  8. CORE PHASE: Evaluation of the safety profile of pasireotide s.c (AEs)

    Incidence of AEs for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid.

    Time frame: for 12 weeks

  9. EXTENSION PHASE: evaluation of the safety profile of pasireotide s.c. during the whole extension period: (AEs)

    Incidence of AEs for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid.

    Time frame: for 36 weeks

  10. CORE PHASE: Evaluation of the safety profile of pasireotide s.c (Labs)

    Incidence of laboratory findings for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid. Changes from baseline in laboratory values and vital signs

    Time frame: for 12 weeks

  11. EXTENSION PHASE: evaluation of the safety profile of pasireotide s.c. during the whole extension period: (Labs)

    Incidence of laboratory findings for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid. Changes from baseline in laboratory values and vital signs

    Time frame: for 36 weeks

  12. CORE PHASE: Evaluation of the safety profile of pasireotide s.c (ECG)

    Incidence of ECG findings for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid. Changes from baseline in ECG readings,

    Time frame: for 12 weeks

  13. EXTENSION PHASE: evaluation of the safety profile of pasireotide s.c. during the whole extension period: (ECG)

    Incidence of ECG findings for pasireotide s.c. 50 µg, or 100 µg or 200 µg tid or placebo tid. Changes from baseline in ECG readings,

    Time frame: for 36 weeks

  14. CORE PHASE: Evaluation of the safety profile of pasireotide s.c (imaging)

    Changes from baseline in gallbladder imaging

    Time frame: for 12 weeks

  15. EXTENSION PHASE: evaluation of the safety profile of pasireotide s.c. during the whole extension period:(imaging)

    Changes from baseline in gallbladder imaging

    Time frame: for 36 weeks

07

Study locations

29 sites
  • Stanford University School of Medicine, Endocrinology, 800 Welch Road,
    Palo Alto, California 94305, United States
  • Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60628, United States
  • NOLA Care
    Metairie, Louisiana 70006, United States
  • Velocity Clinical Research - Annapolis
    Annapolis, Maryland 21401, United States
  • Joslin Diabetes CenterJoslin Diabetes Center, One Joslin Place
    Boston, Massachusetts 02215, United States
  • Mayo Clinic - Rochester, 200 First Street, SW, 55905
    Rochester, Minnesota 55905, United States
  • Montefiore Medical Center, 111 E 210th Street,
    The Bronx, New York 10467, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr,
    San Antonio, Texas 78229, United States
  • University of Wisconsin Health W. E. Clinic END, 451 Junction Rd,
    Madison, Wisconsin 53717, United States
  • Universitaire Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology,Herestraat 49
    Leuven, 3000, Belgium
  • AP-HP Hopital Europeen Georges Pompidou, 20, rue Leblanc,
    Paris, 75015, France
  • HCL Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Hopital Rangueil, Attachée de Recherche Clinique, Centre Investigation Clinique, CHU, Cedex 9, France
    Toulouse, 31059, France
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
    Bologna, 40138, Italy
  • Azienda Ospedale - Università Padova, Clinica Medica 3, Via Giustiniani, 2,
    Padova, 35128, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, Italy
  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, L.go Gemelli 8
    Rome, Italy
  • Hospital Universitario Vall d'Hebron, Passeig Vall d´Hebron 119-129, Spain
    Barcelona, 08035, Spain
  • Hospital Clinic Barcelona, Lipid Clinic End, Nutr. Service Hospital Clinic, C. Villarroel, 170,
    Barcelona, 08036, Spain
  • Hospital Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitari de Girona Dr. Josep Trueta
    Girona, Spain
  • Hospital Clinico San Carlos, C/ Prof Martin Lagos s/n, Spain
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • North Bristol NHS Trust
    Bristol, BS10 5NB, United Kingdom
  • King's College Hospital NHS Foundation Trust, Denmark Hill, SE5 9RS
    London, EC1A 1AA, United Kingdom
  • Hammersmith Hospital
    London, W12 OHS, United Kingdom
  • Guy's Hospital
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Oct 2026, 33 months after the start.

Of 24 phase 2 interventional studies under Hypoglycemia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2023
First posted
Jul 3, 2023
StartActual
Jan 4, 2024
Primary completionEst.
Oct 29, 2026
CompletionEst.
Oct 29, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05928390
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Jan 4, 2024
Primary completion
Oct 29, 2026 (estimated)
Completion
Oct 29, 2026 (estimated)
Last update
Sep 17, 2026

Study contacts

Arnd H MUELLER, MD
study director · Recordati AG

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion